LIFR

Across TCGA pan-cancer cohorts, LIFR mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated LIFR data layer compared with 25 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher LIFR mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated LIFR expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

LSCC, PDAC, and LUAD are the cancer types where LIFR mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	All	0.888	1.000	.005	10	view →
PDAC	OS	Median	All	0.306	0.855	.007	8	view →
LUAD	DFS	Median	III,IV	1.000	0.498	.017	3	view →
CCRCC	OS	Median	All	0.952	0.769	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

LIFR–LSCC (DFS)

Open the LSCC breakdown →